The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...
All in all, PHAT has 6 recent analyst reviews that break down into 5 Buys and 1 Hold, giving the stock a Strong Buy consensus rating. The shares are priced at $17.66 and have an average price target ...
Zacks Investment Research on MSN
RARE rises on completion of rolling submission for AAV gene therapy
Shares of Ultragenyx Pharmaceutical RARE were up 15.5% yesterday following the completion of the rolling submission of a ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...
Ultragenyx (RARE) announced that it has completed the rolling submission of its biologics license application to the FDA, seeking approval for ...
Advances delivered what may feel like medical miracles, including the first bladder transplant, a lifesaving personalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback